COLL
What one share of Collegium Pharmaceutical holds
Pharmaceutical Preparations
Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain.
Collegium Pharmaceutical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $22.33 |
|---|---|
| Profit | $1.45 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | $9.07 |
| Cash and investments | $3.98 |
| Debt | $7.35 |
| Book value | $9.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.07 | −$3.88 | $0.02 | −$3.11 | — | $4.59 |
| 2017 | $0.94 | −$2.47 | $0.03 | −$2.25 | — | $3.18 |
| 2018 | $8.51 | −$1.19 | $0.17 | $4.97 | — | $2.75 |
| 2019 | $8.87 | −$0.68 | $0.19 | $0.64 | — | $2.60 |
| 2020 | $8.82 | $0.76 | $0.16 | $2.51 | — | $5.37 |
| 2021 | $6.75 | $1.86 | $0.05 | $2.48 | — | $6.03 |
| 2022 | $13.71 | −$0.74 | $0.05 | $3.62 | — | $5.76 |
| 2023 | $13.56 | $1.29 | $0.01 | $6.56 | — | $6.13 |
| 2024 | $15.62 | $1.86 | $0.04 | $5.03 | — | $7.28 |
| 2025 | $19.66 | $1.73 | $0.04 | $8.25 | — | $9.51 |